Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab

Hepatitis B virus (HBV) reactivation in the setting of rituximab use is a potentially fatal but preventable safety event. The rate of HBV screening and proportion of patients at risk who receive antiviral prophylaxis in patients initiating rituximab is unknown. We analyzed electronic health record (...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmajuk, Gabriela, Tonner, Chris, Trupin, Laura, Li, Jing, Sarkar, Urmimala, Ludwig, Dana, Shiboski, Stephen, Sirota, Marina, Dudley, R. Adams, Murray, Sara, Yazdany, Jinoos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380298/
https://www.ncbi.nlm.nih.gov/pubmed/28353614
http://dx.doi.org/10.1097/MD.0000000000006528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380298/
https://www.ncbi.nlm.nih.gov/pubmed/28353614
http://dx.doi.org/10.1097/MD.0000000000006528

Ejemplares similares